Looking at the press release in the Onyx website, I see that the only "new data" to be presented in Kyota are for trials of opromozib in hematological malignancies. (This presentation has already taken place, I think. We might recall that there were a lot of hints in the last CC that they place a lot of importance on this oral proteasome inhibitor.) For Kyrpolis, their major presentation is a study of Kyrpolis in combination with Revlimid and low-dose dexamethasone in high-risk smoldering myeloma in the elderly. This is moving Kyrpolis way up in the order of battle. I imagine that these patients, being elderly, are not candidates for stem cell transplants and therefore the various treatment cycles (Velcade, chemotherapy, etc.) which precede it. The theory here, I gather, would be to throw the three least noxious drugs at them in combination to see if this will slow their progression to fullblown MM.
Note the 5 "thumbs down" to a fairly nonargumentative post. These yutzes are so mad about being short one of the few stocks that rallied today, they'd give me a thumbs down for posting the date. They should realize that the runup today was only the first part of what should be a more sustained rally as the importance of this trial is recognized more widely.